Never Run Out Of Buyers To Sell To.

AbTis is a biotechnology company with a proprietary linker platform, AbClick®, which enables the development of site-selective antibody conjugate therapies for the targeted delivery of diverse therapeutic payloads. Through AbClick®, AbTis has established a simple yet cost-efficient conjugation process that empowers the expansion of diverse forms of bioconjugate treatments, such as ADC, ARC, DAC, and others, all without modifying the antibody. AbClick® also allows for precise control over key parameters such as half-life, DAR, and linker-payload stability, which are all essential for designing…
Annual Revenue$10M to $25M
Estimated OwnershipBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.